This clinical trial is focused on studying vulvar cancer, a type of cancer that affects the external female genitalia. The trial is investigating the safety of using a combination of chemotherapy and radiation therapy, known as chemoradiation, as a treatment for early-stage vulvar cancer. The study aims to see if chemoradiation can safely replace a more invasive surgical procedure called inguinofemoral lymphadenectomy, which involves removing lymph nodes in the groin area. This approach is being tested in patients who have a macrometastasis, which means a cancer spread larger than 2mm, in the sentinel lymph node, a key lymph node that cancer cells are likely to spread to first.

The trial involves the use of two chemotherapy drugs: cisplatin and carboplatin. These drugs are given as a solution through an intravenous (IV) infusion, which means they are delivered directly into the bloodstream through a vein. The study will observe patients over a period to monitor the safety and effectiveness of this treatment approach. The main goal is to see if this method can prevent the recurrence of cancer in the groin area, while also looking at other factors such as treatment-related side effects, survival specific to the disease, and the quality of life reported by patients.

The trial is expected to continue until March 2029, with the recruitment of participants having started in July 2019. By participating in this study, researchers hope to gather important information that could lead to less invasive treatment options for patients with early-stage vulvar cancer, potentially improving their overall treatment experience and outcomes.